MX2017011399A - Métodos para modular la densidad ósea. - Google Patents

Métodos para modular la densidad ósea.

Info

Publication number
MX2017011399A
MX2017011399A MX2017011399A MX2017011399A MX2017011399A MX 2017011399 A MX2017011399 A MX 2017011399A MX 2017011399 A MX2017011399 A MX 2017011399A MX 2017011399 A MX2017011399 A MX 2017011399A MX 2017011399 A MX2017011399 A MX 2017011399A
Authority
MX
Mexico
Prior art keywords
bone density
methods
modulating bone
subject
preventing
Prior art date
Application number
MX2017011399A
Other languages
English (en)
Inventor
Shapiro David
Luciano Adorini
Original Assignee
Intercept Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intercept Pharmaceuticals Inc filed Critical Intercept Pharmaceuticals Inc
Publication of MX2017011399A publication Critical patent/MX2017011399A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a métodos para tratar reducir el riesgo de prevenir o aliviar un síntoma de una enfermedad o afección asociada con cambios en la densidad ósea, osteoporosis o una enfermedad ostepénica, o para inducir la ontogénesis o el crecimiento de hueso, o para ralentizar, prevenir o invertir la reducción de la densidad ósea en un sujeto que necesita este tratamiento, que comprende administrar al sujeto un compuesto de la invención.
MX2017011399A 2015-03-09 2016-03-08 Métodos para modular la densidad ósea. MX2017011399A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562130144P 2015-03-09 2015-03-09
PCT/US2016/021344 WO2016144946A1 (en) 2015-03-09 2016-03-08 Methods for modulating bone density

Publications (1)

Publication Number Publication Date
MX2017011399A true MX2017011399A (es) 2018-03-16

Family

ID=56879295

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017011399A MX2017011399A (es) 2015-03-09 2016-03-08 Métodos para modular la densidad ósea.

Country Status (12)

Country Link
US (1) US20180042943A1 (es)
EP (1) EP3268009A4 (es)
JP (1) JP2018507880A (es)
KR (1) KR20170125927A (es)
CN (1) CN107530361A (es)
AU (1) AU2016229906A1 (es)
CA (1) CA2978916A1 (es)
HK (1) HK1243646A1 (es)
IL (1) IL254197A0 (es)
MX (1) MX2017011399A (es)
SG (1) SG11201707328SA (es)
WO (1) WO2016144946A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201812382D0 (en) 2018-07-30 2018-09-12 Nzp Uk Ltd Compounds
US10919162B2 (en) 2018-12-26 2021-02-16 Ford Global Technologies, Llc Systems and methods for efficient power management of modular mobile robot platforms with replaceable batteries
DE102020101118A1 (de) 2019-01-18 2020-07-23 Ford Global Technologies, Llc Mobile mehrzweckroboter und verfahren zu deren verwendung

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003223214B2 (en) * 2002-03-01 2008-09-18 Celltech R & D, Inc. Methods to increase or decrease bone density
WO2003080803A2 (en) * 2002-03-21 2003-10-02 Smithkline Beecham Corporation Methods of using farnesoid x receptor (fxr) agonists
CL2007003035A1 (es) * 2006-10-24 2008-05-16 Smithkline Beechman Corp Compuestos derivados de isoxazol sustituidos, agonistas de receptores farnesoid x; procedimiento de preparacion; composicion farmaceutica que lo comprende; y uso del compuesto en el tratamiento de la obesidad, diabetes mellitus, fibrosis en organos,
JP2012072095A (ja) * 2010-09-29 2012-04-12 Tokyo Institute Of Technology 骨形成促進剤
DK3336097T3 (da) * 2012-06-19 2020-09-28 Intercept Pharmaceuticals Inc Fremstilling af ikke-krystallinsk obeticholsyre
WO2014021694A1 (ko) * 2012-08-03 2014-02-06 서울대학교 산학협력단 골 관련 질환 예방 및 치료를 위한 조성물
CA2912139C (en) * 2013-05-14 2021-04-20 Roberto Pellicciari 11-hydroxyl-derivatives of bile acids and amino acid conjugates thereof as farnesoid x receptor modulators

Also Published As

Publication number Publication date
EP3268009A1 (en) 2018-01-17
IL254197A0 (en) 2017-10-31
SG11201707328SA (en) 2017-10-30
WO2016144946A1 (en) 2016-09-15
US20180042943A1 (en) 2018-02-15
EP3268009A4 (en) 2018-12-12
CA2978916A1 (en) 2016-09-15
HK1243646A1 (zh) 2018-07-20
JP2018507880A (ja) 2018-03-22
KR20170125927A (ko) 2017-11-15
AU2016229906A1 (en) 2017-09-21
CN107530361A (zh) 2018-01-02

Similar Documents

Publication Publication Date Title
MX2018004947A (es) Metodos para el tratamiento de sindrome de angelman y de los trastornos relacionados.
MX2022007221A (es) Compuestos y composiciones para el tratamiento o prevencion de trastornos patologicos asociados con exceso de deposicion de fibrina y/o formacion de trombos.
GB2541571A (en) Pharmaceutical compositions
MX2017008844A (es) Terapia de combinacion con inhibidor de acetil-coa carboxilasa (acc) para el tratamiento de enfermedad de higado graso no alcoholico.
MX2017005252A (es) Metodos para la preparacion de ribosidos.
MD20170073A2 (ro) Terapii combinate pentru tratarea cancerelor
EA201790142A1 (ru) Лечение лейкоза ингибиторами гистондеацетилазы
EA201891340A1 (ru) Лечение рака с использованием 2-дезокси-2-фтор-l-фукозы в комбинации с ингибитором контрольных точек
MX2019013808A (es) Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cancer.
MA40458A (fr) Méthodes de traitement du cancer du col de l'utérus
PH12015502815A1 (en) Use of sigma receptor ligands for the prevention and treatment of pain associated to interstitial cystitis/bladder pain syndrome (ic/bps)
MX2017000306A (es) Metodos para tratar hipotension.
MX2017016114A (es) Metodos para tratar o prevenir una proteopatia.
MX2016015378A (es) Uso de eribulina en el tratamiento de cancer.
MX2017011399A (es) Métodos para modular la densidad ósea.
MX2020001164A (es) Composicion para su uso en la prevencion y/o el tratamiento de la mucositis orogastrointestinal inducida por un tratamiento oncologico.
JO3541B1 (ar) علاجات طبية قائمة على اناموريلين
MX2016015695A (es) Metodos para tratar y prevenir enfermedades de inestabilidad vascular.
TW201613639A (en) Methods for treating cardiovascular diseases
TW201613569A (en) Composition consisting of kukoamine A and/or kukoamine B and method of using thereof
MX2018011379A (es) Tratamiento del prurito uremico.
MY198753A (en) Treatment of androgen deprivation therapy associated symptoms
WO2016182812A8 (en) Activation of neuronal store-operated calcium entry pathway for the treatment of alzheimer's disease
TW201611844A (en) Combination therapy
PH12014501044A1 (en) Methods for improved wound closure employing olivamine and human umbilical vien endothelial cells